<span item_type="fundamental" item_id="32ad794a2cef917390562353d410ca0f" counter_id="ST/US/RCEL" env="prod"></span><span item_type="announcement" item_id="615414148274656513" env="prod"></span><p>Revenue: As of FY2025 Q4, the actual value is USD 17.62 M.</p><p>EPS: As of FY2025 Q4, the actual value is USD -0.38, beating the estimate of USD -0.4015.</p><p></p><h3>Fourth Quarter 2025 Financial Highlights</h3><h4>Total Revenue</h4><p>AVITA Medical, Inc. reported total revenue of $17.6 million in the fourth quarter of 2025, a decrease from $18.4 million in the fourth quarter of 2024, primarily due to reimbursement headwinds <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. Sales revenue was $17,431 thousand, and lease revenue was $185 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Gross Profit Margin</h4><p>The gross profit margin was 81.2% for the fourth quarter of 2025, compared to 87.6% in Q4 2024, reflecting product mix and inventory-related adjustments <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. The RECELL-only gross margin for the quarter was 83.1% <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Operating Expenses</h4><p>Total operating expenses decreased by 5% to $24.7 million in Q4 2025, from $26.1 million in Q4 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. Sales and marketing expenses were - $11,938 thousand, general and administrative expenses were - $7,090 thousand, and research and development expenses were - $5,691 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Operating Loss</h4><p>The operating loss for Q4 2025 was - $10,407 thousand, compared to - $9,957 thousand in Q4 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Net Loss</h4><p>The net loss was - $11.6 million in Q4 2025, consistent with - $11.6 million in Q4 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Net Use of Cash</h4><p>Net use of cash improved for the second consecutive quarter to approximately $5.1 million in Q4 2025, compared to $6.2 million in the third quarter and $10.1 million in the second quarter <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Cash and Marketable Securities</h4><p>AVITA Medical, Inc. ended Q4 2025 with $18.2 million in cash and marketable securities, down from $23.3 million at the start of the quarter and $35.9 million at the end of 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. Cash and cash equivalents were $10,243 thousand, and marketable securities were $7,942 thousand as of December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h3>Full-Year 2025 Financial Highlights</h3><h4>Total Revenues</h4><p>Total revenues for the full year 2025 increased by 11% to $71.6 million, up from $64.3 million in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. Sales revenue was $70,879 thousand, and lease revenue was $731 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Gross Profit Margin</h4><p>The gross profit margin for full year 2025 was 82.1%, compared to 85.8% in the prior year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. The RECELL products only gross margin was 84.3% for the year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Operating Expenses</h4><p>Total operating expenses decreased by 9% to $101.4 million in 2025, from $111.8 million in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. Sales and marketing expenses were - $53,138 thousand, general and administrative expenses were - $27,373 thousand, and research and development expenses were - $20,839 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Operating Loss</h4><p>The operating loss for FY 2025 was - $42,534 thousand, an improvement from - $56,593 thousand in FY 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h4>Net Loss</h4><p>The net loss was - $48.6 million for full year 2025, an improvement from - $61.8 million in the prior year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h3>Debt and Capital Structure</h3><p>In January 2026, AVITA Medical, Inc. refinanced its existing debt under a new credit facility with Perceptive Advisors LLC, securing up to $60 million of committed capital <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. An initial $50 million was funded, with an option for an additional $10 million through Q1 2027, subject to a revenue milestone <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. The new credit facility includes trailing twelve-month (TTM) revenue covenants, with an initial TTM revenue covenant of $68.5 million for Q1 2026 and $73 million for the full year 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. To comply with the initial TTM revenue covenant, AVITA Medical, Inc. needs to achieve $15.4 million in revenue in Q1 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p><h3>Outlook / Guidance</h3><p>AVITA Medical, Inc. expects full-year 2026 revenue to be in the range of $80 million to $85 million, representing an anticipated growth of approximately 12% to 19% compared to 2025 revenue <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>. The company aims for consistent, execution-led growth quarter by quarter, focusing on deeper utilization within core burn and trauma centers <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-ex99_1.htm"></span>.</p>

Avita Medical | 8-K: FY2025 Q4 Revenue: USD 17.62 M